Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. 2021

Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
Center for Molecular Medicine Cologne, University of Cologne, Köln, Germany. katharina.leuchte@uk-koeln.de.

Thermal ablative therapies are standard treatments for localized hepatocellular carcinoma (HCC). In addition to local tumor destruction, ablation leads to abscopal effects in distant lesions most likely mediated by an anti-tumor immune response. Although microwave ablation (MWA) is increasingly substituting other ablative techniques, its systemic immunostimulatory effects are poorly studied. We analyzed tumor-specific immune responses in peripheral blood of HCC patients after thermal ablation with regard to T cell responses and disease outcome. While comprehensive flow cytometric analyses in sequential samples of a prospective patient cohort (n = 23) demonstrated only moderate effects of MWA on circulating immune cell subsets, fluorospot analyses of specific T cell responses against seven tumor-associated antigens (TTAs) revealed de-novo or enhanced tumor-specific immune responses in 30% of patients. This anti-tumor immune response was related to tumor control as Interferon-y and Interleukin-5 T cell responses against TAAs were more frequent in patients with a long-time remission (> 1 year) after MWA (7/16) compared to patients suffering from an early relapse (0/13 patients) and presence of tumor-specific T cell response (IFN-y and/or IL-5) was associated to longer progression-free survival (27.5 vs. 10.0 months). Digital image analysis of immunohistochemically stained archival HCC samples (n = 18) of patients receiving combined MWA and resection revealed a superior disease-free survival of patients with high T cell abundance at the time of thermal ablation (37.4 vs. 13.1 months). Our data demonstrates remarkable immune-related effects of MWA in HCC patients and provides additional evidence for a combination of local ablation and immunotherapy in this challenging disease.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008872 Microwaves That portion of the electromagnetic spectrum from the UHF (ultrahigh frequency) radio waves and extending into the INFRARED RAYS frequencies. EHF Waves,Extremely High Frequency Radio Waves,Micro Wave,Micro Waves,Ultrahigh Frequency Waves,Microwave Radiation,EHF Wave,Micro Waves,Microwave,Microwave Radiations,Radiation, Microwave,Ultrahigh Frequency Wave,Wave, EHF,Wave, Micro,Wave, Ultrahigh Frequency,Waves, Micro
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas

Related Publications

Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
March 2024, Oncology letters,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
January 2007, Oncology,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
November 2015, World journal of hepatology,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
December 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
March 2021, Clinical imaging,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
October 2015, Experimental and therapeutic medicine,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
November 2019, Liver cancer,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
October 2000, Zhonghua yi xue za zhi,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
November 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association,
Katharina Leuchte, and Elena Staib, and Martin Thelen, and Philipp Gödel, and Axel Lechner, and Peter Zentis, and Maria Garcia-Marquez, and Dirk Waldschmidt, and Rabi Raj Datta, and Roger Wahba, and Christian Wybranski, and Thomas Zander, and Alexander Quaas, and Uta Drebber, and Dirk Ludger Stippel, and Christiane Bruns, and Michael von Bergwelt-Baildon, and Kerstin Wennhold, and Hans Anton Schlößer
May 2022, Clinical imaging,
Copied contents to your clipboard!